A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs PRCL 02 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors PRCL Research Inc
- 03 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 26 Sep 2018 Status changed from not yet recruiting to recruiting.
- 20 Sep 2018 Planned initiation date changed from 21 Sep 2018 to 1 Oct 2018.